✦ LIBER ✦

Thrombocytopenia in pegylated interferon and ribavirin combination therapy for chronic hepatitis C

✍ Scribed by Aizawa, Nobuhiro; Enomoto, Hirayuki; Takashima, Tomoyuki; Sakai, Yoshiyuki; Iwata, Kazunari; Ikeda, Naoto; Tanaka, Hironori; Iwata, Yoshinori; Saito, Masaki; Imanishi, Hiroyasu; Iijima, Hiroko; Nishiguchi, Shuhei

Book ID: 121621274
Publisher: Springer Japan
Year: 2013
Tongue: English
Weight: 302 KB
Volume: 49
Category: Article
ISSN: 0944-1174
DOI: 10.1007/s00535-013-0884-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Thrombocytopenia in pegylated interferon

Thrombocytopenia in pegylated interferon and ribavirin combination therapy for chronic hepatitis C

✍ Aizawa, Nobuhiro; Enomoto, Hirayuki; Takashima, Tomoyuki; Sakai, Yoshiyuki; Iwat 📂 Article 📅 2013 🏛 Springer Japan 🌐 English ⚖ 302 KB

Interferon-ribavirin combination therapy

Interferon-ribavirin combination therapy for chronic hepatitis C

✍ Solko W. Schalm; J. T. Brouwer; L. Chemello; A. Alberti; A. Bellobuono; G. Ideo; 📂 Article 📅 1996 🏛 Springer US 🌐 English ⚖ 466 KB

Combination therapy with pegylated inter

Combination therapy with pegylated interferon plus ribavirin in the treatment of hepatitis C virus-related thrombocytopenia

✍ Tarkan Karakan; Mehmet Cindoruk; Bulent Degertekin; Ibrahim Dogan; Alper Sancak; 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 470 KB

Current therapy for hepatitis C: pegylat

Current therapy for hepatitis C: pegylated interferon and ribavirin

✍ McHutchison, John G; Fried, Michael W 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 108 KB

Pegylated interferon plus ribavirin in c

Pegylated interferon plus ribavirin in chronic hepatitis c

✍ Bruce R. Bacon 📂 Article 📅 2001 🏛 Springer 🌐 English ⚖ 38 KB

Merimepodib, pegylated interferon, and r

Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders

✍ Vinod K. Rustgi; William M. Lee; Eric Lawitz; Stuart C. Gordon; Nezam Afdhal; Fr 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 240 KB 👁 1 views

on behalf of the MErimepodib TRiple cOmbination (METRO) study group Merimepodib (MMPD) is an orally administered, inosine monophosphate dehydrogenase inhibitor that has shown antiviral activity in nonresponders with chronic hepatitis C (CHC) when combined with pegylated interferon alfa 2a (Peg-IFN-a